| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
This study is a validation study for our previous predictive study using onset threshold (Ohkuchi A, et al. Hypertens Res 2013; 36: 1073). We measured plasma levels of sFlt-1, PlGF, and the sFlt-1/PlGF ratio at 19-25, and 26-31 weeks of gestation in 127 high risk women, using ECLIA method. The primary outcome was the subsequent onset of preeclampsia (PE) after the blood sampling. As for the blood sampling at 19-25 weeks of gestation, the onset threshold (OT) of plasma level of sFlt-1/PlGF ratio yielded the sensitivity of 0/1 (0%), and specificity of 120/120 (100%). As for the blood sampling at 26-31 weeks of gestation, the OT yielded the sensitivity of 1/1 (100%), and specificity of 80/80 (100%). Thus, the usage of onset threshold of sFlt-1/PlGF ratio at 19-31 weeks of gestation may be clinically useful to rule out the imminent onset of PE within 4 weeks after the blood sampling.
|
